Galderma Group N (SW:GALD) — Market Cap & Net Worth
Market Cap & Net Worth: Galderma Group N (GALD)
Galderma Group N (SW:GALD) has a market capitalization of $37.01 Billion (CHF29.28 Billion) as of May 2, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #719 globally and #11 in its home market, demonstrating a 8.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galderma Group N's stock price CHF163.80 by its total outstanding shares 234823853 (234.82 Million). Analyse Galderma Group N operating cash flow efficiency to see how efficiently the company converts income to cash.
Galderma Group N Market Cap History: 2024 to 2026
Galderma Group N's market capitalization history from 2024 to 2026. Data shows growth from $29.88 Billion to $48.63 Billion (70.72% CAGR).
Galderma Group N Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galderma Group N's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.13x
Galderma Group N's market cap is 11.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
94.53x
Galderma Group N's market cap is 94.53 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $29.88 Billion | $4.44 Billion | $231.00 Million | 6.73x | 129.34x |
| 2025 | $48.12 Billion | $4.32 Billion | $509.09 Million | 11.13x | 94.53x |
Competitor Companies of GALD by Market Capitalization
Companies near Galderma Group N in the global market cap rankings as of May 2, 2026.
Key companies related to Galderma Group N by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Galderma Group N Historical Marketcap From 2024 to 2026
Between 2024 and today, Galderma Group N's market cap moved from $29.88 Billion to $ 48.63 Billion, with a yearly change of 70.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF48.63 Billion | +1.05% |
| 2025 | CHF48.12 Billion | +61.07% |
| 2024 | CHF29.88 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Galderma Group N was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.01 Billion USD |
| MoneyControl | $37.01 Billion USD |
| MarketWatch | $37.01 Billion USD |
| marketcap.company | $37.01 Billion USD |
| Reuters | $37.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galderma Group N
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more